Clinical Trial Update: AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of AZD2171 (cediranib) in children with recurrent, progressive, or refractory primary central nervous system tumors has completed, presenting safe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Astrocytoma
• Atypical Teratoid Rhabdoid Tumor
• Central Nervous System Germ Cell Tumor
• Ependymoma
• Medulloblastoma
• Meningioma
• Oligodendroglioma

Drugs mentioned

• AZD2171 (cediranib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor | Phase 1 | Status: COMPLETED